Genfit And PBC: Is Elafibranor A Contender? [Seeking Alpha]
Albireo Pharma, Inc. (ALBO)
Last albireo pharma, inc. earnings: 3/2 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.albireopharma.com/investor-relations
Company Research
Source: Seeking Alpha
Summary Any man or institution that tries to rob me of my dignity will lose-Nelson Mandela Investment Thesis Genfit ( OTCPK:GNFTF ) is a small cap ($686M) French clinical stage biopharmaceutical company focused on the early diagnosis and preventive treatment of cardiometabolic disorders of high unmet medical needs. Elafibranor, the lead investigative drug candidate, is in Phase 3 clinical trial for NASH and in Phase 2 clinical trials for pediatric NASH as well as primary biliary cholangitis (PBC), the focus of this article . Elafibranor is a new generation dual PPAR-a/d agonist that lack PPAR-? responses and is devoid of serious adverse events typically associated with some first generation PPAR agonists. Elafibranor positively regulates bile acid, glucose and lipid homeostasis where an imbalance can lead to cholestasis, metabolic syndrome and, possibly, NASH. PBC continues to be an incurable disease. At present, only two FDA approved drugs, ursodeoxycholic acid
Show less
Read more
Impact Snapshot
Event Time:
ALBO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALBO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALBO alerts
High impacting Albireo Pharma, Inc. news events
Weekly update
A roundup of the hottest topics